Description
PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
Article: PP52 Daratumumab: Blessing for the patient, but hell for the clinical lab
€2.42
Related products
-
Article: Highlights in urologic cancer
€2.42 Add to cart -
Article: Highlights in gynaecological cancers
€2.42 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€2.42 Add to cart -
Article: INTRODUCTION
€2.42 Add to cart
